Skip to main content

Advertisement

SpringerLink
Log in

Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis

  • Urology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

The efficacy and safety of vibegron, which is a novel β3-adrenoceptor agonist, need to be systematically evaluated in the treatment of overactive bladder (OAB) patients. This study aimed to assess, using meta-analytic methods, the efficacy and safety of vibegron for OAB compared with placebo or antimuscarinics, considering all available data from comparative studies.

Methods

A systematic search was performed on MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials database to identify studies from their date of inception before 15 March 2020. Meta-analysis was performed based on eligible studies.

Results

Six studies derived from four clinical trials with 4314 randomized patients were finally included in our analysis. We found that vibegron 50 mg and 100 mg were both significantly more efficacious than placebo for all efficacy outcomes. Furthermore, no significant differences were found between vibegron 50 mg or 100 mg and placebo for all the AEs assessed. In addition, the efficacy between vibegron 50 mg or 100 mg and antimuscarinics were comparable except for voided volume. Moreover, vibegron was associated with a decreased risk of dry mouth and an increased risk of nasopharyngitis versus antimuscarinics. Our study also demonstrated that the vibegron 50 mg and 100 mg were equally effective and safe across all the efficacy and AEs’ outcomes.

Conclusions

Vibegron is effective and safe for treating patients with OAB. Based on the current evidence, we recommended that the initial use of vibegron 50 mg was the optimal algorithm in the pharmacologic management of OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336

    Article  CAS  PubMed  Google Scholar 

  2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760–766

    Article  CAS  PubMed  Google Scholar 

  3. Sexton CC, Notte SM, Maroulis C et al (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 65(5):567–585

    Article  CAS  PubMed  Google Scholar 

  4. Chapple CR, Nazir J, Hakimi Z et al (2017) Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol 72(3):389–399

    Article  CAS  PubMed  Google Scholar 

  5. Kelleher C, Hakimi Z, Zur R et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 74(3):324–333

    Article  CAS  PubMed  Google Scholar 

  6. Edmondson SD, Zhu C, Kar NF et al (2016) Discovery of vibegron: a potent and selective beta3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem 59(2):609–623

    Article  CAS  PubMed  Google Scholar 

  7. Di Salvo J, Nagabukuro H, Wickham LA et al (2017) Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther 360(2):346–355

    Article  PubMed  Google Scholar 

  8. Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T (2018) Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 73(5):783–790

    Article  CAS  PubMed  Google Scholar 

  9. Mitcheson HD, Samanta S, Muldowney K et al (2019) Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol 75(2):274–282

    Article  CAS  PubMed  Google Scholar 

  10. Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr (2020) International phase III, randomized, double-blind, placebo- and active-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 101097JU0000000000000807

  11. Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T (2018) Long-term safety and efficacy of the novel beta3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study. Int J Urol 25(7):668–675

    Article  CAS  PubMed  Google Scholar 

  12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269 (W264)

    Article  PubMed  Google Scholar 

  13. Qiu C, Zhao X, She L et al (2019) Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids Health Dis 18(1):54

    Article  PubMed  PubMed Central  Google Scholar 

  14. Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The cochrane collaboration, 2011. Available from www.cochrane-handbook.org

  15. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed  PubMed Central  Google Scholar 

  16. Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66(3):529–541

    Article  PubMed  Google Scholar 

  17. Yoshida M, Takeda M, Gotoh M et al (2019) Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. Int J Urol 26(3):369–375

    Article  CAS  PubMed  Google Scholar 

  18. Yoshida M, Takeda M, Gotoh M et al (2020) Efficacy of vibegron, a novel beta3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int 125(5):709–717

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. La Rosa VL, Duarte de Campos da Silva T, Rosa de Oliveira A, Marques Cerentini T, Viana da Rosa P, Telles da Rosa LH (2020) Behavioral therapy versus drug therapy in individuals with idiopathic overactive bladder: a systematic review and meta-analysis. J Health Psychol 25(5):573–585

    Article  PubMed  Google Scholar 

  20. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388–1395

    Article  PubMed  Google Scholar 

  21. Vitale SG, Capriglione S, Zito G et al (2019) Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet 299(2):299–315

    Article  PubMed  Google Scholar 

  22. Kruppa J, Kavvadias T, Amann S, Baessler K, Schuessler B (2016) Short and long-term urodynamic and quality of life assessment after nerve sparing radical hysterectomy: a prospective pilot study. Eur J Obstet Gynecol Reprod Biol 201:131–134

    Article  PubMed  Google Scholar 

Download references

Funding

This article is supported by grants from 1.3.5 project for disciplines of excellence, West China Hospotal, Sichuan University (ZYGD18011, ZY2016104 and ZYJC18015).

Author information

Authors and Affiliations

  1. Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People’s Republic of China

    Zhongyu Jian, Chi Yuan, Hong Li & Kunjie Wang

  2. West China Biomedical Big Data Center, Sichuan University, Chengdu, People’s Republic of China

    Zhongyu Jian & Wei Zhang

Authors
  1. Zhongyu Jian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chi Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kunjie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JZ: project development, data collection and management, manuscript writing, and revising; YC: data collection, data analysis; LH: data collection, and data analysis; ZW: data collection and data analysis; WK: project design and development, data interpretation, manuscript editing, and revising. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Kunjie Wang.

Ethics declarations

Conflict of interest

The authors of this article as well as all the included studies declare that they have no conflict of interest.

Ethical standards

The study protocol is compliant with ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 508 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jian, Z., Yuan, C., Li, H. et al. Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis. Int Urol Nephrol 52, 2215–2221 (2020). https://doi.org/10.1007/s11255-020-02536-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02536-5

Keywords

Search

Navigation